MENU
ABVC
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

ABVC stock forecast, quote, news & analysis

ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
ABVC
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for ABVC with price predictions
Oct 28, 2026

ABVC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 15, 2026

ABVC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 41 cases where ABVC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ABVC as a result. In 70 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for ABVC just turned positive on October 22, 2026. Looking at past instances where ABVC's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.

ABVC moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ABVC crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

Following a +11.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABVC advanced for three days, in 197 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABVC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ABVC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.824) is normal, around the industry mean (3.151). P/E Ratio (-3.759) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (27.397) is also within normal values, averaging (439.237).

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. ABVC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABVC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 58 to 134.26B. VRTX holds the highest valuation in this group at 134.26B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -12%. KPTI experienced the highest price growth at 96%, while AARD experienced the biggest fall at -66%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 44%. For the same stocks of the Industry, the average monthly volume growth was 37% and the average quarterly volume growth was -6%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 66
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: 0 (-100 ... +100)
ABVC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 15, 2026